Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts Vanda's MAA for Fanaptum

Dec. 23, 2015

EMA CHMP recommends approval of Sanofi Pasteur MSD's hexavalent vaccine Vaxelis

Dec. 22, 2015

EMA committee supports approval of Shield's Feraccru to treat iron deficiency anemia

Dec. 22, 2015

CHMP recommends approval of Lilly's necitumumab and ramucirumab

Dec. 22, 2015

EMA committee backs approval of Brilique 60 mg for patients with history of heart attack

Dec. 21, 2015

EMA CHMP recommends approval of AstraZeneca's osimertinib for NSCLC

Dec. 21, 2015

Bayer's recombinant factor VIII BAY-81-8973 receives positive CHMP opinion

Dec. 21, 2015

EMA committee recommends approval of lesinurad for hyperuricemia in gout

Dec. 21, 2015

Committee backs E.U. orphan drug designation for axalimogene filolisbac in anal cancer

Dec. 16, 2015

EMA supports E.U. orphan drug designation for Aduro Biotech's CRS-207 and GVAX pancreas

Dec. 16, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...